GBS Inc. (NASDAQ: GBS) saw its shares climb at the open Wednesday. The life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabetes Research Institute of Sutter Health’s Mills-Peninsula Medical Center (MPMC) in San Mateo, California.
GBS will perform subsequent statistical analyses of the correlation of glucose levels among these sample types.
Daniel Brown, Head of Clinical Affairs for GBS stated, “While a systematic literature review reveals numerous clinical investigations of salivary glucose levels, we at GBS believe that this is the first clinical study to utilize an independent, validated, traceable reference measurement to characterize glucose in oral fluids.
“We are privileged to collaborate with the Diabetes Research Institute and Johns Hopkins University to complete this important research and thank them in their support in this study. We look forward to continued statistical analysis of the data generated during this study.”
The clinical study followed an IRB-approved protocol. In all, 40 adult subjects with type 2 diabetes were recruited for the study. The subjects represented a distribution of gender and age.
Nearly 1,400 samples of blood and oral fluids were collected and analyzed.
GBS used independent glucose measurement procedures to quantitate glucose in oral fluids and blood, in order to characterize the degree of agreement among the various sample types.
GBS shares tacked on six cents, or 8.5%, to 77 cents.
